Global News

Pfizer: endpoints not met in first phase III study of bapineuzumab for Alzheimer’s

Tuesday, July 24, 2012 02:54 PM

Pfizer has announced the co-primary clinical endpoints—change in cognitive and functional performance compared to placebo—were not met in the Janssen Alzheimer Immunotherapy R&D (Janssen AI)-led phase III trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 302). Pfizer and Janssen AI are partners in the Alzheimer's Immunotherapy Program (AIP).

More... »

Boehringer Ingelheim acquires Funxional's FX125L and somatotaxin portfolio

Monday, July 23, 2012 03:49 PM

Boehringer Ingelheim has agreed to acquire global rights to Funxional Therapeutics’ FX125L compound and somatotaxin program.

More... »

Cell Medica secures $26.5M to establish U.S. operations and fund cell therapy development

Monday, July 23, 2012 03:04 PM

Cell Medica, a London-based cell therapeutics company, has secured a $26.5 million equity investment to launch new operations in Texas focusing on cancer immunotherapy and to continue development of its immune reconstitution cell therapies in Europe.

More... »

Techsol’s ‘QuickLaunch’ aims to achieve faster early-phase clinic automation

Monday, July 23, 2012 02:25 PM

Techsol, a technology service provider for the pharmaceutical and life sciences industry, has released “QuickLaunch,” an accelerated Oracle Health Sciences' LabPas deployment package that enables pharmaceutical companies, CROs and academic medical research institutions to swiftly automate their current early phase clinical units in compliance with the FDA.

More... »

DSM inks South American biologics contract manufacturing agreement

Monday, July 23, 2012 12:46 PM

DSM Pharmaceutical Products, a custom manufacturing and technology business of Royal DSM, has signed a biologics contract manufacturing agreement with its first Brazilian client, Recepta Biopharma, a Sao Paulo-based biotechnology company focused on monoclonal antibodies to treat cancer.

More... »

Analysis: Disparity between number of children with major diseases and pediatric studies

Monday, July 23, 2012 11:54 AM

New analysis shows there are major discrepancies between the amount of pediatric clinical research for several major global diseases and the number of children who suffer from those diseases. While children bear nearly 60% of the burden of 10 major global diseases, only about 12% of the clinical trials for those diseases include or focus on children, according to Boston Children's Hospital doctors Kenneth Mandl and Florence Bourgeois’s analysis of five years of clinical trial data.

More... »

Novavax, PATH to produce vaccines for low-income countries

Monday, July 23, 2012 11:26 AM

Novavax, a clinical-stage biopharmaceutical company based in Rockville, Md., has partnered with international non-profit organization PATH to develop a vaccine against respiratory syncytial virus (RSV) — the most common cause of childhood respiratory infection globally — for infants in low-income countries with a high disease burden.

More... »

Berkery Noyes releases M&A report for healthcare/pharma IT industry

Friday, July 20, 2012 01:15 PM

Berkery Noyes, an independent mid-market investment bank, has released its first half 2012 mergers and acquisitions trend report for the healthcare/pharma information and technology Industry.

More... »

Advocacy groups launch global action agenda for ending AIDS

Friday, July 20, 2012 01:08 PM

Two of the world's leading AIDS advocacy organizations have released a global action agenda to accelerate progress toward ending AIDS.  The agenda identifies five major short-term priorities for global AIDS programs together with realistic, annual targets that must be achieved through 2015.

More... »

Quintiles Global Commercial Solutions opens in Brazil

Thursday, July 19, 2012 02:36 PM

To help biopharmaceutical companies enter the rapidly growing Brazilian biopharmaceutical market, Quintiles has opened its Global Commercial Solutions business in Brazil, offering customized sales forces, market penetration strategies and product solutions.

More... »